Cell Encapsulation Markets 2019-2030: Focus on Therapeutics and Technologies – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cell
Encapsulation: Focus on Therapeutics and Technologies, 2019-2030”
report has been added to ResearchAndMarkets.com’s
offering.

The ‘Cell Encapsulation: Focus on Therapeutics and Technologies,
2019-2030’ report features an extensive study of the current market
landscape and the future potential of encapsulated cell therapies and
affiliated technologies. It is worth mentioning that the study also
provides insights on therapy products wherein other active drug
substances have been encapsulated within living cells.

One of the key objectives of the report was to understand the primary
growth drivers and estimate the future size of the market. Based on
likely licensing deal structures and agreements that are expected to be
signed in the foreseen future, we have provided an informed estimate on
the likely evolution of the market for the period 2019-2030.

In addition, we have provided information on (potential) sales-based
revenues generated by encapsulated cell therapies that are currently in
late stages of development for the treatment of different chronic
disorders, based on parameters, such as target consumer segments, likely
adoption rates, and expected pricing.

The report features likely distribution of the current and forecasted
opportunity across [A] different therapeutic areas (eye disorders,
metabolic disorders, neurological disorders, and oncological disorders),
[B] target disease indications (ataxia telangiectasia, breast cancer,
diabetes, glaucoma, head and neck cancer, macular telangiectasia,
pancreatic cancer, Parkinson’s disease, and retinitis pigmentosa), [C]
type of encapsulation material used (alginate-based microcapsules,
cellulose hydrogels, medical-grade plastics, and red blood cells), and
[D] key geographical regions (North America, Europe and Asia Pacific).

To account for the uncertainties associated with the development of
novel therapeutic products and to add robustness to our model, we have
provided three forecast scenarios, portraying the conservative, base and
optimistic tracks of the market’s evolution.

Amongst other elements, the report features:

• A detailed assessment of the current market landscape of encapsulated
  cell therapies and affiliated technologies, highlighting various
  target disease indications, phase of development, encapsulation
  method, type of cells / API, and route of administration, along with
  information on various stakeholder companies that are developing novel
  encapsulation methods / techniques for use in storage and
  transportation of cells, as well as other applications.
• Comprehensive profiles of industry players that are currently engaged
  in the preclinical / clinical development of their proprietary
  encapsulated cell therapies, featuring an overview of the company, its
  financial information (if available), and a detailed description of
  its product(s), highlighting mechanism of action, current development
  status, and key preclinical / clinical trial results. Each profile
  also includes a list of recent developments, highlighting the key
  milestones achieved, partnership activity, and the likely strategies
  that may be adopted by these players to fuel growth in the foreseeable
  future.
• An in-depth analysis of the patents that have been published related
  to cell encapsulation technologies, since 2013. The analysis also
  highlights the key trends associated with these patents, across patent
  type, regional applicability, CPC classification, emerging focus
  areas, leading industry players (in terms of the number of patents
  filed/granted), and current intellectual property-related benchmarks
  and valuation.
• A comprehensive clinical trial analysis of completed, ongoing and
  planned studies of various encapsulated cell therapies. The analysis
  highlights the key trends associated with these clinical studies
  across various parameters, such as trial start year, trial status,
  phase of development, leading industry and non-industry players (in
  terms of number of trials conducted), study design, target therapeutic
  area, key indications, study focus, clinical endpoints, and enrolled
  patient population and regional distribution of trials.
• An analysis of the partnerships that have been established in the
  domain in the period 2013-2018, covering R&D collaborations, licensing
  agreements, mergers and acquisitions, product development and/or
  commercialization agreements, manufacturing agreements, clinical trial
  agreements, process development agreements, and other relevant deals.
• An analysis of the investments made at various stages of development,
  such as seed financing, venture capital financing, debt financing,
  grants, capital raised from IPOs and subsequent offerings received by
  companies that are focused in this area. The report also features a
  detailed study on the various grants that have been awarded to
  research institutes in this field.
• An analysis highlighting potential strategic partners (for instance,
  manufacturers) for encapsulated therapy developers based on multiple
  parameters, such as therapeutic focus overlap, cell type overlap,
  research programs, existing collaborations, and developer strength

For more information about this report visit https://www.researchandmarkets.com/r/rmefs5

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Biomaterials